High-dose regimen of interleukin-2 and interferon-alpha in combination with lymphokine-activated killer cells in patients with metastatic renal cell cancer

Journal of Immunotherapy

Volumn 20, Issue 4, 1997, Pages 312-320

  Kruit, W H J ^a   Goey, S H ^a   Gratama, J W ^a   Visser, B ^a   Schmitz, P I M ^a   Eggermont, A M M ^a   Bolhuis, R L H ^a   Stoter, G ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Interferon alpha; Interleukin 2; Metastatic renal carcinoma

Indexed keywords

RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT INTERLEUKIN 2;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL PROTOCOL; CLINICAL TRIAL; DEATH; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; FEASIBILITY STUDY; FEMALE; HUMAN; HYPOTENSION; INFECTION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CARCINOMA; LEUKAPHERESIS; LUNG EDEMA; LYMPHOKINE ACTIVATED KILLER CELL; MAJOR CLINICAL STUDY; MALE; METASTASIS; NEPHROTOXICITY; PRIORITY JOURNAL;

ADOPTIVE TRANSFER; ADULT; AGED; CARCINOMA, RENAL CELL; FEMALE; HUMANS; INTERFERON-ALPHA; INTERLEUKIN-2; KIDNEY NEOPLASMS; KILLER CELLS, LYMPHOKINE-ACTIVATED; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS;

EID: 0031464658     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-199707000-00008     Document Type: Article

References (44)

1. Fisher RI, Coltman CA, Doroshow JH, et al. Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. Ann Intern Med 1988;108:518-23.
2. Rosenberg SA, Lotze MT, Yang JC, et al. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989;210:474-85.
3. Negrier S, Philip T, Stoter G, et al. Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: A report of a European multicenter study. Eur J Cancer Clin Oncol 1989;25:21-8.
4. West WH. Continuous infusion recombinant interleukin-2 (rIL2) in adoptive cellular therapy of renal carcinoma and other malignancies. Cane Treat Rev 1989;16:83-9.
5. Gaynor ER, Weiss GR, Margolin KA, et al. Phase I study of high-dose continuous-infusion recombinant interleukin-2 and autologous lymphokine-activated killer cells in patients with metastatic or unresectable malignant melanoma and renal cell carcinoma. J Natl Cancer Inst 1990;82:1397-1442.
6. Von der Maase H, Geertsen P, Thatcher N, et al. Recombinant interleukin-2 in metastatic renal cell carcinoma - a European multicenter phase II study. Eur J Cancer 1991;27:1583-9.
7. Osterwalder B. Clinical studies with interleukin-2: an overview. In: Veronesi U, ed. Lymphohaematopoietic growth factors in cancer therapy II. Berlin: Springer-Verlag, 1992:57-86.
8. Weiss GR, Margolin KA, Aronson FR, et al. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection in-terleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma. J Clin Oncol 1992;10:275-81.
9. Foon KA, Walther PJ, Bernstein ZP, et al. Renal cell carcinoma treated with continuous-infusion interleukin-2 with ex vivo-activated killer cells. J Immunother 1992;11:184-90.
10. Rosenberg SA, Lotze MT, Yang JC, et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 1992;85:622-32.
11. Atkins MB, Sparano J, Fisher RI, et al. Randomised phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma. J Clin Oncol 1993;11:661-70.
12. Quesada JR, Rios A, Swanson DA, et al. Antitumor activity of recombinant-derived interferon-α in metastatic renal cell carcinoma. J Clin Oncol 1985;3:1522-8.
13. Krown SE. Interferon treatment of renal cell carcinoma: current status and future prospects. Cancer 1987;59:647-51.
14. Muss HB. Interferon therapy for renal cell carcinoma. Semin Oncol 1987;14:36-42.
15. Brunda MJ, Bellantoni D, Sulich V. In vivo antitumor activity of combinations of interferon-a and interleukin-2 in a murine model: correlation of efficacy with the induction of cytotoxic cells resembling natural killer cells. Int J Cancer 1987;40:365-71.
16. Cameron RB, McIntosh JK, Rosenberg SA. Synergistic antitumor effects of combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid α-interferon in the treatment of established murine hepatic metastases. Cancer Res 1988; 48: 5810-7.
17. Iigo M, Sakurai J, Tamura T, et al. In vivo antitumor activity of multiple injections of recombinant interleukin-2 alone and in combination with three different types of recombinant interferon on various syngeneic murine tumors. Cancer Res 1988;48:260-4.
18. Rosenberg SA, Lotze MT, Yang JC, et al. Combination therapy with interleukin-2 and alpha interferon for the treatment of patients with advanced cancer. J Clin Oncol 1989;7:1863-74.
19. Mittelman A, Huberman M, Puccio C, et al. A phase I study of recombinant human interleukin-2 and alpha-interferon-2a in patients with renal cell cancer, colorectal cancer, and malignant melanoma. Cancer 1990;66:664-9.
20. Hirsh M, Lipton A, Harvey H, et al. Phase I study of interleukin-2 and interferon-α2a as outpatient therapy for patients with advanced malignancy. J Clin Oncol 1990;8:1657-63.
21. Figlin RA, Belldegrun A, Moldawer M., et al. Concomitant administration of recombinant human interleukin-2 and recombinant interferon alfa-2A: an active outpatient regimen in metastatic renal cell carcinoma. J Clin Oncol 1992;10:414-21.
22. Aronson FR, Sznol M, Atkins MB, et al. A phase II trial of interleukin-2, interferon-alpha and lymphokine-activated killer cells for advanced renal cell carcinoma. [Abstract], Proc Am Soc Oncol 1990;9:183.
23. Negrier S, Mercatello A, Bret M, et al. Intensive regimen of cytokines with interleukin-2 and interferon alfa-2b in selected patients with metastatic renal carcinoma. J Immunother 1995; 17: 62-8.
24. Lamers CHJ, Stoter G, Goey SH, Oosterom R, Bolhuis RLH. Bio-availability of interleukin-2 after reconstitution with albumin. Lancet 1992;340:241.
25. WHO handbook for reporting results of cancer treatment. Geneva: World Health Organization, 1979.
26. Gratama JW, Schmitz PIM, Goey SH, et al. Modulation of immune parameters in patients with metastatic renal cell cancer, receiving combination immunotherapy (IL2, IFNα and autologous Reactivated lymphocytes). Int J Cancer 1996;65:152-60.
27. Stoter G, Goey SH, Kruit WHJ, et al. Combination immunotherapy with interleukin-2 (IL2), alpha-interferon (alFN), and autologous IL-2-activated lymphocytes (LAK) in metastatic renal cell cancer. In: Bukowski RM, Finke JH, Klein EA, eds. Biology of renal cell carcinoma. New York: Springer Verlag, 1995:224-34.
28. Cotran RS, Pober JS, Gimbrone MA, et al. Endothelial activation during interleukin-2 immunotherapy: a possible mechanism for the vascular leak syndrome. J Immunol 1987;139:1883-8.
29. de Boer JP, Wolbink GJ, Thijs LG, Baars JW, Wagstaff J, Hack CE. Interplay of complement and cytokines in the pathogenesis of septic shock. Immunopharmacology 1992;24:135-448.
30. Janssen RAJ, Mulder NH, The TH, de Leij L. The immunobio-logical effects of interleukin-2 in vivo. Cancer Immunol Immunother 1994;39:586-9.
31. Palmer PA, Vinke J, Evers P, et al. Continuous infusion of recombinant interleukin-2 with or without autologous lymphokine activated killer cells for the treatment of advanced renal cell carcinoma. Eur J Cancer 1992;28A: 1038-44.
32. Rosenberg SA, Yang JC, Topalian SL, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. JAMA 1994;271:907-13.
33. Gore ME, Galligioni E, Keen CW, et al. The treatment of metastatic renal cell carcinoma by continuous intravenous infusion of recombinant interleukin-2. Eur J Cancer 1994;30A:329-33.
34. Escudier B, Ravaud A, Fabbro M, et al. High-dose interleukin-2 two days a week for metastatic renal cell carcinoma: a FNCLCC multicenter study. J Immunother 1994;16:306-12.
35. Fyfe G, Fisher RI, Rosenberg SA, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995; 13: 688-96.
36. Whitehead RP, Wolf MK, Solanki DL, et al. A phase II trial of continuous-infusion recombinant interleukin-2 in patients with advanced renal cell carcinoma; a Southwest Oncology Group Study. J Immunother 1995;18:104-14.
37. Parkinson DR, Fisher RI, Rayner AA, et al. Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells: phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimen. J Clin Oncol 1990;8:1630-6.
38. Dillman RO, Church C, Oldham RK, et al. Inpatient continuous-infusion interleukin-2 in 788 patients with cancer: the national biotherapy study group experience. Cancer 1993;71:2358-70.
39. McCabe MS, Stablein D, Hawkins MJ, et al. The modified group C experience, phase III randomized trials of IL2 versus IL2/LAK in advanced renal cell carcinoma and advanced melanoma. Proc Am Soc Clin Oncol 1991; 10:213.
40. Murray Law T, Motzer RJ, Mazumdar M, et al. Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer 1995;76:824-32.
41. Ilson DH, Motzer RJ, Kradin RL, et al. A phase II trial of inter leukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma. J Clin Oncol 1992;10:1124-30.
42. Budd GT, Murthy S, Finke J, et al. Phase I trial of high-dose bolus interleukin-2 and interferon alfa-2a in patients with metastatic malignancy. J Clin Oncol 1992;10:804-9.
43. Marineóla FM, White DE, Wise AP, et al. Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer. J Clin Oncol 1995;13:1110-22.
44. Fosså SD, Auné H, Baggerud E, et al. Continuous intravenous interleukin-2 infusion and subcutaneous interferon-α in metastatic renal cell carcinoma. Eur J Cancer 1993;29A:1313-5.